Cosciens Biopharma Inc (CSCIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Sales | 11 | 6,175 | 33,660 | 36,050 | 27,700 |
| Cost of Goods | N/A | 51 | 26,820 | 27,560 | 18,700 |
| Gross Profit | 11 | 6,124 | 6,840 | 8,490 | 9,000 |
| Operating Expenses | 37,406 | 33,651 | 34,660 | 41,240 | 34,910 |
| Operating Income | -37,395 | -27,476 | -27,000 | -32,190 | -25,210 |
| Interest Expense | 0 | 1,512 | 0 | 0 | 20 |
| Other Income | 20,319 | 1,748 | 6,590 | 6,230 | 2,020 |
| Pre-tax Income | -17,076 | -27,240 | -20,410 | -25,960 | -23,210 |
| Income Tax | 111 | N/A | 0 | 1,100 | 0 |
| Net Income Continuous | -17,187 | -27,240 | -20,412 | -27,067 | -23,218 |
| Net Income Discontinuous | 623 | 34,055 | 0 | 0 | 0 |
| Net Income | $-16,564 | $6,815 | $-20,410 | $-27,060 | $-23,210 |
| EPS Basic Total Ops | -2,806.00 | 2,312.00 | -10,300.00 | -17,396.52 | -18,596.28 |
| EPS Basic Continuous Ops | -2,913.05 | -9,241.26 | -10,206.00 | -16,916.88 | -17,860.00 |
| EPS Basic Discontinuous Ops | 105.59 | 11,553.27 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -2,806.00 | 2,312.00 | -10,300.00 | -17,396.52 | -18,596.28 |
| EPS Diluted Continuous Ops | -2,913.05 | -9,241.26 | -10,206.00 | -16,916.88 | -17,860.00 |
| EPS Diluted Discontinuous Ops | 105.59 | 11,553.27 | N/A | N/A | N/A |
| EBITDA(a) | $-36,517 | $-32,573 | $-25,810 | $-29,320 | $-23,620 |